鹭燕医药(002788) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥74,964,101, representing a 37.43% increase year-over-year[7]. - Operating revenue for the period was ¥3,954,712,910.02, up 27.95% from the same period last year[7]. - Basic earnings per share were ¥0.23, reflecting a 35.29% increase compared to the same period last year[7]. - The weighted average return on equity was 4.39%, an increase of 0.74% from the previous year[7]. - The net profit attributable to shareholders of the listed company increased by 44.15% year-on-year, reflecting strong sales growth and improved profitability[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 43.47% year-on-year, indicating enhanced operational efficiency[17]. - The company reported a net profit of CNY 531,357,048.23, compared to CNY 463,474,120.86, reflecting a growth of about 14.6%[35]. - Net profit for the current period was ¥74,567,103.22, an increase of 42.5% compared to ¥52,339,011.89 in the prior period[38]. - Net profit for the period was ¥196,603,331.38, representing a 42.2% increase from ¥138,263,001.61 in the same period last year[46]. Revenue and Costs - Total operating revenue for the current period reached ¥3,954,712,910.02, an increase of 27.9% compared to ¥3,090,768,311.28 in the previous period[37]. - Total operating costs amounted to ¥3,852,071,215.13, up 27.2% from ¥3,025,758,272.08 in the prior period[37]. - Total operating revenue for the period reached ¥11,127,773,412.17, an increase of 32.4% compared to ¥8,405,134,384.26 in the previous period[44]. - Total operating costs amounted to ¥10,841,019,180.87, up 32.0% from ¥8,208,125,465.69 in the prior period[44]. Cash Flow - The net cash flow from operating activities was -¥80,365,490.59, a decrease of 156.29% compared to the previous year[7]. - The cash inflow from operating activities totaled CNY 11,802,238,688.34, an increase from CNY 9,301,159,908.08 in the previous period, representing a growth of approximately 27%[54]. - The net cash flow from operating activities was negative at CNY -728,811,581.82, worsening from CNY -80,389,688.28 in the prior period[54]. - The cash outflow for purchasing goods and services was CNY 11,700,553,448.87, up from CNY 8,849,662,528.97, indicating a rise of about 32.9%[54]. - The net cash flow from investing activities was CNY -166,319,314.32, compared to CNY -261,623,692.63 in the previous period, showing an improvement of approximately 36.4%[55]. - The cash inflow from financing activities was CNY 3,861,097,947.06, an increase from CNY 2,912,166,429.18, reflecting a growth of about 32.5%[55]. - The net cash flow from financing activities was CNY 771,227,714.28, significantly higher than CNY 194,096,360.85 in the previous period, marking an increase of approximately 297%[55]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥7,296,943,859.49, an increase of 20.20% compared to the previous year[7]. - The company's accounts receivable at the end of the reporting period amounted to RMB 3,724.51 million, an increase of 33.66% compared to the end of the previous year[16]. - Total liabilities increased to CNY 5,455,224,369.36, up from CNY 4,416,939,154.54, representing a growth of approximately 23.5% year-over-year[30]. - Current liabilities totaled CNY 5,280,095,580.94, compared to CNY 4,214,739,692.90, indicating a rise of about 25.3%[30]. - Owner's equity amounted to CNY 1,841,719,490.13, up from CNY 1,653,577,487.12, marking an increase of around 11.4%[30]. - The company's current assets totaled approximately CNY 6.07 billion, up from CNY 4.98 billion at the end of 2018, indicating a growth of approximately 21.8%[27][28]. - Total liabilities reached CNY 4,416,939,154.54, with current liabilities at CNY 4,214,739,692.90 and non-current liabilities at CNY 202,199,461.64[64]. Shareholder Information - The total number of shareholders at the end of the reporting period was 26,705[10]. - The largest shareholder, Xiamen Maidi Ken Technology Co., Ltd., holds 35.34% of shares, totaling 115,506,840 shares[10]. - The company implemented a capital increase, raising total shares from 192,253,200 to 326,830,440[8]. - The company has committed to gradually reducing its shareholdings after the lock-up period, with plans to complete this within 24 months[19]. Research and Development - Research and development expenses increased significantly to ¥1,278,053.76 from ¥506,175.35, reflecting a growth of 152.5%[37]. - Research and development expenses increased to ¥3,284,649.64, up from ¥1,604,911.79, reflecting a focus on innovation[44]. Other Financial Metrics - The company reported non-operating income of ¥665,826.68 for the period[9]. - The company reported a credit impairment loss of ¥4,888,935.11, compared to no losses in the previous period[38]. - The company experienced a significant increase in sales expenses, which rose to ¥76,626,591.59 from ¥56,861,732.04, marking a 34.8% increase[37]. - The company reported an investment loss of ¥94,863.03, a decline from an investment gain of ¥276,944.54 in the previous period[37]. - Other comprehensive income after tax was ¥1,011,522.17, slightly down from ¥1,210,219.69 in the previous year[46].